natgillin/translations-raw huggingface dataset:
MIU = million international units; TIW = three times a week. a: p value based on Cochran-Mantel Haenszel Chi square test. b: p value based on chi-square test. c: subjects &lt; 75 kg received 100 µg/week ViraferonPeg and subjects ≥ 75 kg received 150 µg/week ViraferonPeg. d: ribavirin dosing was 800 mg for patients &lt; 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients &gt; 75 kg.
IU = milijun internacionalnih jedinica; a: p-vrijednost dobivena Cochran-Mantel Haenszelovim hi-kvadrat testom; b: p-vrijednost dobivena hi-kvadrat testom. c: ispitanici teški &lt; 75 kg primali su 100 μg lijeka ViraferonPeg na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg lijeka ViraferonPeg na tjedan. d: doza ribavirina iznosila je 800 mg za bolesnike &lt; 60 kg, 1000 mg za bolesnike 60-75 kg, te 1200 mg za bolesnike &gt; 75 kg.
MN Assay All subjects Seronegative subjects at baseline ( &lt; 1:10)
MN analiza Svi ispitanici Ispitanici seronegativni na početku ( &lt; 1:10)
MN results for A/H5N1/Indonesia/5/05 revealed a seroprotection rate of 38% (31-45) in adults (18-60 years) and 14% (8-20) in elderly ( &gt; 60 years); a seroconversion rate of 58% (50-65) in adults and 30% (23-38) in elderly and finally a GMR of 4.67 (3.95-5.56) in adults and 2.19 (1.86-2.58) in elderly.
Rezultati MN analize za virus A/H5N1/Indonesia/5/05 pokazali su stopu seroprotekcije od 38% (31-45) u odraslih osoba (18-60 godina) i 14% (8-20) u starijih osoba ( &gt; 60 godina): stopa serokonverzije od 58% (50-65) u odraslih osoba i 30% (23-38) u starijih osoba te omjer srednje geometrijske vrijednosti (GMR) od 4,67 (3,95-5,56) u odraslih osoba i 2,19 (1,86-2,58) u starijih osoba.
MN results for A/H5N1/Vietnam/1194/2004 revealed a seroprotection rate of 10% (6-16) in adults (18-60 years) and 6% (3-11) in elderly ( &gt; 60 years); a seroconversion rate of 19% (13-25) in adults and 7% (4-13) in elderly and finally a GMR of 1.86 (1.63-2.12) in adults and 1.33 (1.17-1.51) in elderly.
Rezultati MN analize za virus A/H5N1/Vietnam/1194/2004 pokazali su stopu seroprotekcije od 10% (6-16) u odraslih osoba (18-60 godina) i 6% (3-11) u starijih osoba ( &gt; 60 godina): stopu serokonverzije od 19% (13-25) u odraslih osoba i 7% (4-13) u starijih osoba te omjer srednje geometrijske vrijednosti (GMR) od 1,86 (1,63-2,12) u odraslih osoba i 1,33 (1,17-1,51) u starijih osoba.
Moderate (ANC: 0.749 - 0.5 x 109/l) and severe (ANC: &lt; 0.5 x 109/l) neutropenia was observed respectively in 24% (216/887) and 5% (41/887) of patients receiving Pegasys 180 micrograms and ribavirin 1000/1200 milligrams for 48 weeks.
Umjerena neutropenija (ABN: 0,749 - 0,5 x 109/l) zamijećena je u 24% (216/887), a izražena neutropenija (ABN: &lt; 0,5 x 109/l) u 5% (41/887) bolesnika koji su 48 tjedana primali Pegasys u dozi od 180 mikrograma u kombinaciji s ribavirinom od 1000/1200 miligrama.
Moderate and severe renal impairment (creatinine clearance &lt; 60 ml/min) (see section 4.4);
umjereno i teško oštećenje funkcije bubrega (klirens kreatinina &lt; 60 ml/min) (vidjeti dio 4.4);
Moderate and severe renal impairment (patients with eGFR &lt; 60 mL/min/1.73 m2 or CrCl &lt; 60 mL/min), (see sections 4.2 and 4.4);
Umjereno i teško oštećenje bubrežne funkcije (bolesnici s eGFR &lt; 60 mL/min/1,73 m2 ili CrCl &lt; 60 mL/min), (vidjeti dijelove 4.2 i 4.4);
Moderate elevations in transaminase (AST or ALT &gt; 5 to ≤ 8 x ULN) or total bilirubin ( &gt; 3 to ≤ 5 x ULN) levels
Umjereno povišene vrijednosti transaminaza (AST ili ALT &gt; 5 do ≤ 8 x GGN) ili ukupnog bilirubina ( &gt; 3 do ≤ 5 x GGN)
Moderate increases (generally &lt; 400 mL to
Uvidjelo se da su umjerena povišenja (uglavnom &lt; 400 mL do
Moderate renal impairment (30  CLcr &lt; 50 mL/min)
Umjereno oštećenje funkcije bubrega
Moderate renal impairment (30  CLcr &lt; 50 mL/min)
Umjereno oštećenje funkcije bubrega (30  CLcr &lt; 50 mL/min)
Moderate renal impairment (eGFR ≥ 30 to &lt; 60 ml/min/1.73 m2)
Umjereno oštećenje bubrežne funkcije (eGFR ≥ 30 do &lt; 60 ml/min/1,73 m2)
Moderate to severe renal impairment (creatinine clearance ≤ 50 ml/min) or moderate to severe hepatic impairment (Child-Pugh score &gt; 6) (see also section 4.4).
Umjereno do teško oštećenje funkcije bubrega (klirens kreatinina ≤ 50 ml/min) ili umjereno do teško oštećenje funkcije jetre (Child-Pugh score &gt; 6) (vidjeti dio 4.4).
Moderate to severe renal impairment (defined as an estimated creatinine clearance &lt; 60 ml/min).
Umjereno do teško oštećenje bubrega (definiran kao procijenjeni klirens kreatinina &lt; 60 ml/min).
Moderate to severe thrombocytopenia, leucopenia, erythrocytopenia, granulocytopenia, agranulocytosis, haemolytic anaemia and pancytopenia may occur rarely (≥ 1/10,000 to &lt; 1/1,000) (see section 4.4).
Rijetko se mogu razviti umjerena do teška trombocitopenija, leukopenija, eritropenija, granulocitopenija, agranulocitoza, hemolitička anemija i pancitopenija (≥ 1/10 000 i &lt; 1/1000) (vidjeti dio 4.4).
Modest changes in volume of distribution (Vss) and clearance (Cl) have been observed in children between 1 and 3 years of age, leading to a statistically significant shorter elimination half-life (t½, z) than that observed in younger ( &lt; 1 year of age; p = 0.037) or older ( &gt; 3 years of age; p = 0.042) groups.
Umjerene promjene u volumenu distribucije (Vss) i klirensu (Cl) uočene su kod djece u dobi od 1 do 3 godine, što vodi do statistički značajno kraćeg poluvijeka eliminacije (t½, z) nego što je onaj uočen u mlađih ( &lt; 1 godine starosti; p = 0,037) ili starijim ( &gt; 3 godine starosti; p = 0,042) skupinama.
Monitor liver function weekly until transaminases return to &lt; 3 times ULN (Grade 1) or baseline.
Funkciju jetre treba provjeravati svaki tjedan sve dok se transaminaze ne vrate na vrijednosti &lt; 3 puta GGN (1. stupanj) ili na početne vrijednosti.
Monitor transaminases weekly until return to &lt; 3 times ULN or baseline.
Pratiti transaminaze svaki tjedan sve dok se ne vrate na vrijednosti &lt; 3 puta GGN ili na početne vrijednosti.
More frequent dose adjustments (see Tables 1 and 2 above) may be required in patients &gt; 65 years of age (see section 4.8).
U bolesnika starijih od 65 godina možda će biti potrebne češće prilagodbe doze (vidjeti tablice 1 i 2 gore) (vidjeti dio 4.8).
More patients converted to sirolimus developed new onset diabetes mellitus defined as 30 days or longer of continuous or at least 25 days non-stop (without gap) use of any diabetic treatment after randomisation, a fasting glucose ≥126 mg/dL or a non-fasting glucose ≥200 mg/dL after randomisation (18.3% vs 5.6%, p=0.025*).
Više onih koji su prebačeni na sirolimus razvilo je novi nastup diabetesa mellitusa definiran kao 30-dnevna ili dulja neprekidna ili najmanje 25-dnevna neprekidna (bez pauze) primjena bilo koje antidijabetičke terapije nakon randomizacije, s glukozom natašte ≥126 mg/dl ili glukozom mjerenom tijekom dana (bez 8-satnog uzimanja hrane) od ≥200 mg/dl nakon randomizacije (18,3% naspram 5,6%, p &lt; 0.001*).
More patients receiving 25 mg alogliptin (7.8%) achieved target HbA1c levels of  7.0% compared to those receiving placebo (0.8%) at Week 26.
U 26. tjednu je ciljne razine HbA1c od ≤7,0% postiglo više bolesnika koji su primali 25 mg alogliptina (7,8%) nego oni koji su primali placebo (0,8%) (p &lt; 0,001).
More patients who were naïve to previous ACE inhibitor or ARB therapy or on low-dose therapy (equivalent to &lt; 10 mg enalapril/day) were able to achieve and maintain Entresto 200 mg when up-titrated over 6 weeks (84.8%) versus 3 weeks (73.6%).
Više je bolesnika koji nikada prije nisu primali terapiju ACE inhibitorom ili ARB-om ili koji su bili na terapiji niskom dozom (ekvivalentno &lt; 10 mg enalaprila/dan) moglo postići i održati dozu Entresta od 200 mg kada se doza titrirala prema većoj tijekom 6 tjedana (84,8%) u odnosu na 3 tjedna (73,6%).
More patients who were naïve to previous ACE inhibitor or ARB therapy or on low-dose therapy (equivalent to &lt; 10 mg enalapril/day) were able to achieve and maintain Neparvis 200 mg when up-titrated over 6 weeks (84.8%) versus 3 weeks (73.6%).
Više je bolesnika koji nikada prije nisu primali terapiju ACE inhibitorom ili ARB-om ili koji su bili na terapiji niskom dozom (ekvivalentno &lt; 10 mg enalaprila/dan) moglo postići i održati dozu Neparvisa od 200 mg kada se doza titrirala prema većoj tijekom 6 tjedana (84,8%) u odnosu na 3 tjedna (73,6%).
More Simponi-treated patients demonstrated sustained mucosal healing (patients with mucosal healing at both week 30 and week 54) in the 50 mg group (42%, nominal p &lt; 0.05) and 100 mg group (42%, p &lt; 0.005) compared with patients in the placebo group (27%).
Održano cijeljenje sluznice (bolesnici s cijeljenjem sluznice i u 30. i u 54. tjednu) primijećeno je u većeg broja bolesnika liječenih lijekom Simponi u dozi od 50 mg (42%, nominalna p vrijednost &lt; 0,05) i 100 mg (42%, p &lt; 0,005) nego u bolesnika koji su primali placebo (27%).
More than 400 million doses of the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. have been distributed worldwide (1978 to 2003).
Više od 400 milijuna doza prethodnog kombiniranog cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. distribuirano je širom svijeta (od 1978. do 2003.).
More than 518 million doses of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. have been distributed worldwide (1978 to 2007).
Širom svijeta je distribuirano više od 518 milijuna doza cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. (od 1978. do 2007.).
Moreover, in patients with a baseline haemoglobin of &gt; 13 g/dl, the possibility that Retacrit treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded.
Osim toga, kod bolesnika s početnom razinom hemoglobina &gt; 13 g/dl, ne smije se isključiti mogućnost da se liječenje Retacritom može povezati s povećanim rizikom od postoperativnih trombotičkih/vaskularnih događaja.
Mortality in the pivotal studies from disseminated intravascular coagulation (DIC) associated haemorrhage was very common ( &gt; 10%), which is consistent with the early mortality reported in the literature.
U pivotalnim je studijama vrlo često bio prijavljivan ( &gt; 10%) mortalitet zbog krvarenja povezanog s diseminiranom intravaskularnom koagulacijom (DIK), što je u skladu s preuranjenim mortalitetom opisanim u literaturi.
Most atopic dermatitis patients (adults and children) treated with single or repeated application of tacrolimus ointment (0.03-0.1%), and infants from age of 5 months treated with tacrolimus ointment (0.03%) had blood concentrations &lt; 1.0 ng/ml.
Većina bolesnika s atopijskim dermatitisom (odrasli i djeca) liječenih jednokratnom ili ponovljenom primjenom takrolimus masti (0,03-0,1%), i dojenčad u dobi od 5 mjeseci liječena takrolimus mašću (0,03%), imali su koncentracije u krvi &lt; 1,0 ng/ml.
Most cases of peripheral oedema in clinical studies with ambrisentan were mild to moderate in severity, although it may occur with greater frequency and severity in patients ≥65 years.
Tijekom kliničkih ispitivanja, većina je perifernih edema bila blaga do umjerena, ali oni mogu biti češći i teži u bolesnika u dobi &gt; 65 godina.
Most frequently reported moderate or severe adverse reactions in paediatric patients age 2 to &lt; 12 years (reported in 2 or more children, Trial 1182.14, 48 weeks analyses, Full Analysis Set).
Najčešće umjerene ili teške nuspojave u pedijatrijskoj populaciji u dobi od 2 do &lt; 12 godina (prijavljeno za 2 ili više djece, Ispitivanje 1182.14, analize 48 tjedana, svi ispitanici).
Most of the radioactivity recovered in urine ( &gt; 60% of dose) occurred in the first 24 hours.
Većina radioaktivnosti nađene u mokraći ( &gt; 60% doze) javila se unutar prva 24 sata.
Most patients (97%, N=882) had neutropenia at baseline ( &lt; 200 neutrophils/µL).
Većina bolesnika (97%, N = 882) imala je neutropeniju na početku ispitivanja ( &lt; 200 neutrofila/µl).
Most patients ( &gt; 80%) had received at least two phlebotomies in the last 24 weeks prior to screening.
Većina bolesnika ( &gt; 80%) primila je najmanje dvije flebotomije u posljednja 24 tjedna prije probira.
Most patients ( &gt; 89%), in both Groups A and B, achieved complete reversal of the anticoagulant effect of dabigatran as measured by dTT or ECT in the first 4 hours after administration of 5 g idarucizumab.
Većina bolesnika ( &gt; 89%), u obje skupine A i B, postigli su potpuno poništenje antikoagulacijskog učinka dabigatrana prema izmjerenim vrijednostima dTT ili ECT u prva 4 sata nakon primjene 5 g idarucizumaba.
Most patients in the clinical trials ( &gt; 84%) were Caucasian.
Većina bolesnika u kliničkim ispitivanjima ( &gt; 84%) bili su bijelci.
Most resistant patients (72%) had received &gt; 600 mg imatinib.
Većina bolesnika s rezistencijom (72%) primala je &gt; 600 mg imatiniba.
Most subjects were Caucasian ( &gt; 99%) and male (53%), with a median age of 56 years (28% were
Ispitanici su većinom bili bijele rase ( &gt; 99%) i muškarci (53%), medijana starosti od
Mottled red to reddish brown, circular shaped (tablets for dogs 2–4 kg) or rectangular shaped (tablets for dogs &gt; 4–10 kg, tablets for dogs &gt; 10–25 kg and tablets for dogs &gt; 25–50 kg).
Prošarane crvene do smeđe crvenkaste, kružnog (tablete za pse 2 – 4 kg) ili pravokutnog oblika (tablete za pse &gt; 4 – 10 kg, tablete za pse &gt; 10 – 25 kg i tablete za pse &gt; 25 – 50 kg).
Mottled red to reddish brown, circular shaped (tablets for dogs 2–4 kg), or rectangular shaped (tablets for dogs &gt; 4–10 kg, tablets for dogs &gt; 10–25 kg and tablets for dogs &gt; 25–50 kg).
Prošarane crvene do smeđe crvenkaste, kružnog (tablete za pse 2–4 kg) ili pravokutnog oblika (tablete za pse &gt; 4–10 kg, tablete za pse &gt; 10–25 kg i tablete za pse &gt; 25–50 kg).
Multi-drug resistant Mycobacterium tuberculosis (MDRH &amp; R-TB): isolate resistant to at least isoniazid and rifampicin, but susceptible to fluoroquinolones and second line injectable agents.
Multirezistentna Mycobacterium tuberculosis (MDRH &amp; R-TB): izolati rezistentni barem na izonijazid i rifampicin, ali osjetljivi na fluorokinolone i drugu liniju lijekova koji se primjenjuju injekcijom.
Muscoskeletal, connective tissue and bone disorders Common ( &gt; 1/100, &lt; 1/10): arthralgia and myalgia
Poremećaji mišićno-koštanog sustava, vezivnog tkiva i kostiju Često ( &gt; 1/100 i &lt; 1/10): artralgija i mijalgija
Myasthenia gravis-like symptoms have also been reported in &lt; 1% of patients who received higher doses of ipilimumab in clinical trials.
Zabilježeni su i simptomi slični miasteniji gravis u &lt; 1% bolesnika koji su primali ipilimumab u visokim dozama u kliničkim ispitivanjima.
Nadir ANC &lt; 500/mm3 and nadir platelets ≥ 50,000/mm3
Najniži ABN &lt; 500 /mm3 i najniži broj trombocita  50 000 /mm3
Nadir ANC &lt; 500/mm3 and nadir platelets ≥ 50,000/mm3
Najniži ABN &lt; 500/mm3 i najniži broj trombocita ≥ 50,000/mm3
Nadir ANC &lt; 500/mm³ and nadir platelets ≥ 50,000/mm³
Najniži ABN &lt; 500/mm³ i najniži broj trombocita ≥ 50 000/mm³
Nadir ANC &lt; 500/mm3 for &gt; 1 week
Najniža vrijednost ABN &lt; 500/mm3
Nadir ANC &lt; 500/mm3 with neutropenic fever &gt; 38°C
Najniža vrijednost ABN &lt; 500/mm3 i neutropenijska vrućica &gt; 38°C
Nadir platelets &lt; 50,000 /mm3 regardless of nadir ANC
Najniži broj trombocita &lt; 50 000 /mm3 bez obzira na najniži ABN
Nadir platelets &lt; 50,000 /mm3 with bleedinga, regardless of nadir ANC
Najniži broj trombocita &lt; 50 000/mm3 uz krvarenjea, bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm3 regardless of nadir ANC
Najniži broj trombocita &lt; 50 000 /mm3 bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm3 regardless of nadir ANC
Najniži broj trombocita &lt; 50,000/mm3 bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm3 with bleedinga, regardless of nadir ANC
Najniži broj trombocita &lt; 50 000/mm3 uz krvarenjea, bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm3 with bleedinga, regardless of nadir ANC
Najniži broj trombocita &lt; 50,000/mm3 uz krvarenjea, bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm³ regardless of nadir ANC
Najniži broj trombocita &lt; 50 000/mm³ bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm³ with bleedinga, regardless of nadir ANC
Najniži broj trombocita &lt; 50 000/mm³ uz krvarenjea, bez obzira na najniži ABN
Nadir platelets &lt; 50,000 /mm 3 regardless of nadir ANC
Najniži broj trombocita &lt; 50 000 /mm3 bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm 3 with bleedinga, regardless of nadir ANC
Najniži broj trombocita &lt; 50 000/mm3 uz krvarenjea, bez obzira na najniži ABN
Nadir platelets &lt; 50,000/mm3
Najniža vrijednost trombocita
Nadir platelets &lt; 50,000/mm3 with bleedinga, aregardless of nadir ANC
Najniži ABN &lt; 500 /mm3 i najniži broj trombocita ≥ 50 000 /mm3
Nail discolouration; Onycholysis (G3/4: 1%)
&lt; 1%) promjena boje nokta; oniholiza (G 3/4: 1%)
Naloxegol 25 mg dose, compared with placebo, also resulted in greater improvement (change from baseline) of week 12 PAC-SYM rectal domain scores in both studies (p=0.004 and p &lt; 0.001, Kodiac 4 and 5, respectively) and for the stool domain scores in Kodiac 4 (p=0.031) and Kodiac 5 (p &lt; 0.001).
U usporedbi s placebom, doza naloksegola od 25 mg dovela je i do većeg poboljšanja (promjena od početne vrijednosti) PAC-SYM rezultata u 12. tjednu za rektalnu domenu u oba ispitivanja (Kodiac 4 p=0,004; Kodiac 5 p &lt; 0,001), kao i rezultata za domenu stolice u ispitivanjima Kodiac 4 (p=0,031) i Kodiac 5 (p &lt; 0,001).
Naltrexone / bupropion (-3.7%) was significantly (p &lt; 0.001) more efficacious than placebo (-1.7%) treatment in this population.
Naltrekson / bupropion (-3,7 %) je bio značajno (p &lt; 0,001) djelotvorniji u te populacije nego placebo (-1,7 %).
Naltrexone and bupropion are well absorbed from the gastrointestinal tract ( &gt; 90% absorbed), however, naltrexone has a significant first pass effect thereby limiting systemic bioavailablity, with only 5-6% reaching the systemic circulation intact.
Naltrekson i bupropion se dobro apsorbiraju iz gastrointestinalnog sustava ( &gt; 90 % apsorbirani), međutim, naltrekson ima značajan učinak prvog prolaska čime se ograničava sistemska bioraspoloživost, sa samo 5-6 % u sistemskoj cirkulaciji u nepromijenjenom obliku.
Name and address of the manufacturer of the biological active substances
Naziv i adresa proizvođača biološki djelatne &lt; ih &gt; tvari
Name and address of the manufacturer responsible for batch release
Naziv i adresa proizvođača odgovornog &lt; ih &gt; za puštanje serije u promet
Name and address of the manufacturer responsible for batch release Dopharma B.V.
Naziv i adresa proizvođača odgovornog &lt; ih &gt; za puštanje serije u promet Dopharma B.V.
Name and address of the manufacturer responsible for batch release Merck Sharp &amp; Dohme B.V.
Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet Merck Sharp &amp; Dohme B.V.
Name and address of the manufacturer responsible for batch release Zoetis Manufacturing &amp; Research Spain, S.L.
Naziv i adresa proizvođača odgovornog za puštanje serije u promet Zoetis Manufacturing &amp; Research Spain, S.L.
Name and address of the manufacturer responsible for batch release:
Naziv i adresa proizvođača odgovornog &lt; ih &gt; za puštanje serije u promet
Name and address of the manufacturer(s) of the biological active substance(s) Merck Sharp &amp; Dohme Corp.
Naziv(i) i adresa(e) proizvođača biološke(ih) djelatne(ih) tvari Merck Sharp &amp; Dohme Corp.
Name and address of the manufacturer(s) of the biological active substance(s) Zoetis Manufacturing &amp; Research Spain, S.L.
Naziv i adresa proizvođača biološki djelatnih tvari Zoetis Manufacturing &amp; Research Spain, S.L. Ctra.
Name and address of the manufacturer(s) responsible for batch release
Naziv i adresa proizvođača odgovornog &lt; ih &gt; za puštanje serije u promet
Name and address of the manufacturer(s) responsible for batch release Merck Sharp &amp; Dohme B.V.
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet Merck Sharp &amp; Dohme B.V.
Name and address of the manufacturer(s) responsible for batch release Zoetis Manufacturing &amp; Research Spain, S.L.
Naziv i adresa proizvođača odgovornog za puštanje serije u promet Zoetis Manufacturing &amp; Research Spain, S.L.
Name and address of the manufacturers of the biological active substance
Naziv i adresa proizvođača biološki djelatne &lt; ih &gt; tvari
Name and address of the manufacturers responsible for batch release Zoetis Manufacturing &amp; Research Spain, S.L.
Naziv i adresa proizvođača odgovornih za puštanje serije u promet Zoetis Manufacturing &amp; Research Spain, S.L.
Name of Company: Merck Sharp &amp; Dohme Corp.
Naziv tvrtke: Merck Sharp &amp; Dohme Corp.
Name of Company: Merck Sharp and Dohme BV
Naziv tvrtke: Merck Sharp &amp; Dohme BV
Nasal
&lt; 1/10)
NB-304 evaluated subjects with type 2 diabetes not achieving glycaemic goal of HbA1c &lt; 7% (53 mmol/mol) with oral anti-diabetes agents or on diet and exercise alone.
NB-304 je procijenio ispitanike s dijabetesom tipa 2 koji nisu postigli glikemijski cilj od HbA1c &lt; 7 % (53 mmol/mol) s oralnim antidijabeticima ili samo dijetom ili vježbama.
negative positive &lt; baseline positive &gt; baseline
pozitivne &lt; početnih pozitivne &gt; početnih
Negligible amounts ( &lt; 0.001% of maternal blood levels) of talimogene laherparepvec DNA were found in foetal blood.
Nađene su zanemarive količine ( &lt; 0,001% od razine u majčinskoj krvi) DNK virusa talimogene laherparepvec u krvi fetusa.
Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins ( &lt; 10 %).
Levetiracetam kao ni njegov primarni metabolit ne vežu se značajno za proteine plazme ( &lt; 10%).
Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins ( &lt; 10 %).
Levetiracetam, kao ni njegov primarni metabolit, ne vežu se značajno za proteine plazme ( &lt; 10%).
Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins ( &lt; 10%).
Levetiracetam kao ni njegov primarni metabolit ne vežu se značajno za proteine plazme ( &lt; 10%).
Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins ( 10 %).
Levetiracetam kao ni njegov primarni metabolit ne vežu se značajno za proteine plazme ( &lt; 10%).
Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins( &lt; 10 %).
Levetiracetam kao ni njegov primarni metabolit ne vežu se značajno za proteine plazme ( &lt; 10%).
NELSame criteria as for CHR but ANC &gt; 1x109/l and platelets &gt; 20x109/l
NDL Isti kriteriji kao za PHO, ali je ABN1 x 109/l, a trombociti 20 x 109/l
NEOSPHERE is a phase II, multicentre, multinational randomized controlled trial with Perjeta and was conducted in 417 adult female patients with newly diagnosed, early, inflammatory or locally advanced HER2-positive breast cancer (T2-4d; primary tumour &gt; 2cm in diameter) who had not received prior trastuzumab, chemotherapy or radiotherapy.
NEOSPHERE je multicentrično, multinacionalno randomizirano, kontrolirano ispitivanje lijeka Perjeta faze II, u kojem je sudjelovalo 417 odraslih bolesnica s novodijagnosticiranim, ranim, upalnim ili lokalno uznapredovalim HER2 pozitivnim rakom dojke (T2-4d; promjer primarnog tumora &gt; 2 cm) koje prethodno nisu bile liječene trastuzumabom, kemoterapijom ni radioterapijom.
Nephritis occurred in 9 (0.3%) patients, including Grade 2, 3 or 4 cases in 3 (0.1%), 4 (0.1%) and
3 (0,1%) bolesnika, slučajeve 3. stupnja u 4 (0,1%) bolesnika i slučaj 4. stupnja u 1 ( &lt; 0,1%) bolesnika.
Nervous system disorders (Common, ≥1/100 to &lt; 1/10)
Poremećaji živčanog sustava (Često, ≥1/100 do &lt; 1/10)
Neutropenia ( &lt; 750 cells/mm3) was reported in 5%, thrombocytopenia (platelets &lt; 50,000/mm3) in 2%, and low haemoglobin ( &lt; 8 g/dl) in &lt; 1% of patients receiving Zerit.
U 5% bolesnika opisana je neutropenija ( &lt; 750 stanica/mm3), trombocitopenija (trombociti &lt; 50000/mm3) u 2% bolesnika i snižene vrijednosti hemoglobina ( &lt; 8 g/dl) kod &lt; 1% bolesnika koji su primali Zerit.